GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Total Current Assets

Abbisko Cayman (HKSE:02256) Total Current Assets : HK$2,157.2 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Abbisko Cayman's total current assets for the quarter that ended in Dec. 2024 was HK$2,157.2 Mil.


Abbisko Cayman Total Current Assets Historical Data

The historical data trend for Abbisko Cayman's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Total Current Assets Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Assets
Get a 7-Day Free Trial 770.30 3,160.83 2,688.73 2,232.84 2,157.16

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,688.73 2,479.12 2,232.84 2,358.43 2,157.16

Abbisko Cayman Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Abbisko Cayman's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Abbisko Cayman's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Abbisko Cayman  (HKSE:02256) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Abbisko Cayman's Liquidation Value for the quarter that ended in Dec. 2024 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=2092.019-158.775+0.75 * 0+0.5 * 0
=1,933.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abbisko Cayman Total Current Assets Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbisko Cayman Business Description

Traded in Other Exchanges
Address
Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.
Executives
Xu Yao-chang 2101 Beneficial owner
Qiming Corporate Gp Vi, Ltd. 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Chen Zhui 2501 Other
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Shi Yi 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Futu Trustee Limited 2301 Trustee
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Morgan Stanley 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Computershare Hong Kong Trustees Limited 2301 Trustee
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you

Abbisko Cayman Headlines

No Headlines